Clover triple respiratory vaccine triggers RSV, hMPV and PIV3 antibodies in 420-patient Phase 2
Clover’s 420-patient Phase 2 trial found strong antibody responses to RSV, hMPV and PIV3 with no apparent immune interference, supporting further development of its multi-virus vaccines for older adults.